Back

CSL Seqirus reports Phase 3 benefits for 7,699-person influenza vaccine study

Verifying
  • CSL Seqirus published Phase 3 results for its aQIVc influenza vaccine in The Lancet Infectious Diseases.
  • 7,699 adults aged 50 and older participated across eight countries.
  • The trivalent formulation received UK approval earlier in 2026 and European Commission approval.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.